

John D Fisk

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8862389/john-d-fisk-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

197
papers

10,812
citations

50
h-index

100
g-index

212
ext. papers

12,457
ext. citations

3.9
avg, IF

6.25
L-index

#	Paper	IF	Citations
197	A systematic review of the effects of cannabis on cognition in people with multiple sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103338	4	2
196	Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221078497	5	
195	Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis.. <i>Frontiers in Neurology</i> , 2022 , 13, 874724	4.1	0
194	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.. <i>Frontiers in Immunology</i> , 2021 , 12, 794075	8.4	
193	Olfactory Function and Diffusion Tensor Imaging as Markers of Mild Cognitive Impairment in Early Stages of Parkinson's Disease. <i>Clinical EEG and Neuroscience</i> , 2021 , 15500594211058263	2.3	0
192	The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1462-1474	4.5	0
191	Effect of mood and anxiety disorders on health care utilization in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1411-1420	5	1
190	Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1284-1292	5	2
189	Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study. <i>CMAJ Open</i> , 2021 , 9, E510-E521	2.5	2
188	Clinical and neuropathological variability in the rare IVS10+14 tau mutation. <i>Neurobiology of Aging</i> , 2021 , 101, 298.e1-298.e10	5.6	0
187	The association between childhood maltreatment and pain catastrophizing in individuals with immune-mediated inflammatory diseases. <i>Journal of Psychosomatic Research</i> , 2021 , 145, 110479	4.1	1
186	Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 290-302	5	11
185	Impact of Psychiatric Comorbidity on Health Care Use in Rheumatoid Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2021 , 73, 90-99	4.7	3
184	Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 131-140	4.3	4
183	The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1285-1293	4.5	12
182	Response to: Correspondence on Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment by Pamuk and Hasni. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
181	Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer's disease with the presenilin 1 mutation, Leu235Pro. <i>Neurobiology of Aging</i> , 2021 , 103, 31-41	5.6	1

180	Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease. <i>PLoS ONE</i> , 2021 , 16, e0249809	3.7	0
179	Higher Framingham Risk Scores are associated with greater loss of brain volume over time in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 54, 103088	4	0
178	Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 56, 103249	4	1
177	Disease-modifying drugs for multiple sclerosis and subsequent health service use.. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211063403	5	1
176	Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data. <i>Neuroepidemiology</i> , 2020 , 54, 140-147	5.4	5
175	Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review. <i>Crohn's & Colitis 360</i> , 2020 , 2, otz053	1.4	3
174	Pandemic Dementia Scarce Resource Allocation. <i>Canadian Geriatrics Journal</i> , 2020 , 23, 216-218	2.8	7
173	Social phobia in immune-mediated inflammatory diseases. <i>Journal of Psychosomatic Research</i> , 2020 , 128, 109890	4.1	3
172	Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1580-1587	2.4	13
171	Neuropathologic burden and the degree of frailty in relation to global cognition and dementia. <i>Neurology</i> , 2020 , 95, e3269-e3279	6.5	17
170	Spatial normalization of multiple sclerosis brain MRI data depends on analysis method and software package. <i>Magnetic Resonance Imaging</i> , 2020 , 68, 83-94	3.3	6
169	Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020 , 72, 1130-1139	4.7	31
168	Performance of Regression-Based Norms for Cognitive Functioning of Persons With Multiple Sclerosis in an Independent Sample. <i>Frontiers in Neurology</i> , 2020 , 11, 621010	4.1	2
167	Prodrome in relapsing-remitting and primary progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2019 , 26, 1032-1036	6	13
166	Adjusting for differential misclassification in matched case-control studies utilizing health administrative data. <i>Statistics in Medicine</i> , 2019 , 38, 3669-3681	2.3	2
165	Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2019 , 76, 1028-1034	17.2	36
164	Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis. <i>Patient Education and Counseling</i> , 2019 , 102, 1722-1729	3.1	8
163	The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1674-1680	4.5	35

162	Five years before multiple sclerosis onset: Phenotyping the prodrome. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1092-1101	5	35
161	Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 360-368	4.5	87
160	Higher health care use before a clinically isolated syndrome with or without subsequent MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 35, 42-49	4	2
159	Visual and Auditory fMRI Paradigms for Presurgical Language Mapping: Convergent Validity and Relationship to Individual Variables. <i>Neurology Research International</i> , 2019 , 2019, 6728120	1.7	5
158	Cholinergic Neurons in Nucleus Subputaminalis in Primary Progressive Aphasia. <i>Canadian Journal of Neurological Sciences</i> , 2019 , 46, 174-183	1	2
157	Author response: Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. <i>Neurology</i> , 2019 , 93, 1081-1082	6.5	2
156	MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 138-144	4	2
155	Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. <i>Neurology</i> , 2019 ,	6.5	52
154	Diabetes and anxiety adversely affect cognition in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 164-170	4	20
153	Relationship Between DTI Metrics and Cognitive Function in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 436	5.3	42
152	The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1867-1875	4.5	50
151	Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018 , 70, 970-978	4.7	64
150	Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease. <i>General Hospital Psychiatry</i> , 2018 , 51, 71-78	5.6	16
149	The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 20, 9-15	4	69
148	Effects of physical comorbidities on disability progression in multiple sclerosis. <i>Neurology</i> , 2018 , 90, e410-e427	4.2	42
147	Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1641-1648	4.5	6
146	Psychiatric comorbidity is associated with disability progression in multiple sclerosis. <i>Neurology</i> , 2018 , 90, e1316-e1323	6.5	95
145	Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. <i>General Hospital Psychiatry</i> , 2018 , 53, 65-72	5.6	38

144	Factors associated with perceived need for mental health care in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 25, 179-185	4	8
143	Resting State BOLD Variability in Alzheimer's Disease: A Marker of Cognitive Decline or Cerebrovascular Status?. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 39	5.3	24
142	Mining healthcare data for markers of the multiple sclerosis prodrome. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 25, 232-240	4	10
141	Identifying optic neuritis and transverse myelitis using administrative data. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 25, 258-264	4	3
140	The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. <i>PLoS ONE</i> , 2018 , 13, e0198975	3.7	30
139	Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study. <i>JMIR Research Protocols</i> , 2018 , 7, e15	2	17
138	Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018 , 20, 76-84	2.3	19
137	Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 26, 124-156	4	20
136	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. <i>Neuroepidemiology</i> , 2018 , 51, 1-10	5.4	14
135	Increased incidence and prevalence of psoriasis in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 13, 81-86	4	19
134	Infection-related health care utilization among people with and without multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1506-1516	5	51
133	Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. <i>Lancet Neurology</i> , 2017 , 16, 445-451	24.1	74
132	Prevalence of Psychiatric Disorders is Increased Five Years before the Diagnosis in IBD. <i>Gastroenterology</i> , 2017 , 152, S973	13.3	2
131	Longitudinal changes in microstructural white matter metrics in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2017 , 13, 330-338	5.3	68
130	Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. <i>Journal of Psychosomatic Research</i> , 2017 , 101, 17-23	4.1	86
129	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. <i>Neuroepidemiology</i> , 2017 , 48, 124-130	5.4	4
128	Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study. <i>Neurology</i> , 2017 , 89, 2455-2461	6.5	45
127	Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus. <i>Neuropathology and Applied Neurobiology</i> , 2017 , 43, 571-583	5.2	6

126	Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra. <i>Journal of Neurology</i> , 2017 , 264, 1497-1505	5.5	12
125	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 588-596	5	25
124	Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. <i>BMC Research Notes</i> , 2017 , 10, 619	2.3	26
123	Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 685-93	5	20
122	Differing trends in the incidence of vascular comorbidity in MS and the general population. <i>Neurology: Clinical Practice</i> , 2016 , 6, 201-202	1.7	
121	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. <i>Neurology</i> , 2016 , 86, 1287-1295	6.5	63
120	Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity. <i>Neurology</i> , 2016 , 86, 1417-1424	6.5	110
119	Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study. <i>Neurology</i> , 2016 , 86, 1279-1286	6.5	61
118	Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 5, 12-26	4	93
117	Fatigue and Comorbidities in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016 , 18, 96-104	2.3	27
116	Screening Tools for Anxiety in People with Multiple Sclerosis: A Systematic Review. <i>International Journal of MS Care</i> , 2016 , 18, 273-281	2.3	16
115	Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 8, 86-92	4	10
114	Differing trends in the incidence of vascular comorbidity in MS and the general population. <i>Neurology: Clinical Practice</i> , 2016 , 6, 120-128	1.7	31
113	Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. <i>Brain and Behavior</i> , 2016 , 6, e00493	3.4	14
112	High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010). <i>Journal of Neurology</i> , 2015 , 262, 2352-63	5.5	83
111	Comorbidity is associated with pain-related activity limitations in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 470-476	4	30
110	Differences in the burden of psychiatric comorbidity in MS vs the general population. <i>Neurology</i> , 2015 , 85, 1972-9	6.5	81
109	Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study. <i>BMC Health Services Research</i> , 2015 , 15, 161	2.9	1

108 Treatment of neuropsychiatric lupus **2015**, 1107-1111

107 Reliability of regression-based normative data for the oral symbol digit modalities test: an evaluation of demographic influences, construct validity, and impairment classification rates in multiple sclerosis samples. *Clinical Neuropsychologist*, **2014**, 28, 281-99 4.4 27

106 Stability of intraindividual variability as a marker of neurologic dysfunction in relapsing remitting multiple sclerosis. *Journal of Clinical and Experimental Neuropsychology*, **2014**, 36, 455-63 2.1 14

105 The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results. *BMJ Open*, **2014**, 4, e005718 3 29

104 Peripheral dysgraphia: dissociations of lowercase from uppercase letters and of print from cursive writing. *Cognitive and Behavioral Neurology*, **2014**, 27, 31-47 1.6 3

103 Altered functional connectivity and performance variability in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 1453-63 5 17

102 Hand dexterity and direct disease related cost in multiple sclerosis. *Journal of the Neurological Sciences*, **2014**, 341, 51-4 3.2 13

101 MS incidence and prevalence in Africa, Asia, Australia and New Zealand: A systematic review. *Multiple Sclerosis and Related Disorders*, **2014**, 3, 48-60 4 25

100 Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. *BMC Neurology*, **2013**, 13, 16 3.1 96

99 Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. *Multiple Sclerosis and Related Disorders*, **2013**, 2, 355-61 4 28

98 Repeated measurement of the attention components of patients with multiple sclerosis using the Attention Network Test-Interaction (ANT-I): stability, isolability, robustness, and reliability. *Journal of Neuroscience Methods*, **2013**, 216, 1-9 3 17

97 Incidence and prevalence of multiple sclerosis in Europe: a systematic review. *BMC Neurology*, **2013**, 13, 128 3.1 289

96 Intra-individual variability in information processing speed reflects white matter microstructure in multiple sclerosis. *NeuroImage: Clinical*, **2013**, 2, 894-902 5.3 21

95 Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. *Neuroepidemiology*, **2013**, 40, 195-210 5.4 138

94 The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. *Neuroepidemiology*, **2013**, 40, 85-92 5.4 49

93 Psychopathology, Neurodiagnostic Testing, and Imaging **2013**, 382-392

92 Indices of cognitive dysfunction in relapsing-remitting multiple sclerosis: intra-individual variability, processing speed, and attention network efficiency. *Journal of the International Neuropsychological Society*, **2013**, 19, 551-8 3.1 19

91 The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada. *Canadian Journal of Neurological Sciences*, **2013**, 40, 824-831 1 44

90	The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. <i>Canadian Journal of Neurological Sciences</i> , 2013 , 40, 824-31	1	19
89	Psychological well-being in relation to frailty: a frailty identity crisis?. <i>International Psychogeriatrics</i> , 2012 , 24, 1347-53	3-4	50
88	Factors influencing healthy aging with multiple sclerosis: a qualitative study. <i>Disability and Rehabilitation</i> , 2012 , 34, 26-33	2-4	56
87	The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2012 , 1, 162-7	4	13
86	Intra-individual Variability as a Measure of Information Processing Difficulties in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2012 , 14, 77-83	2-3	15
85	Screening for cognitive impairment in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 1371-7	4-1	36
84	Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1310-9	5	97
83	The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data. <i>Neuroepidemiology</i> , 2012 , 39, 135-42	5-4	30
82	Information processing and magnetic resonance imaging indices of brain pathology in multiple sclerosis. <i>International Journal of MS Care</i> , 2012 , 14, 84-91	2-3	7
81	Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. <i>Journal of Neurology</i> , 2011 , 258, 1254-60	5-5	115
80	Social vulnerability and prefrontal cortical function in elderly people: a report from the Canadian Study of Health and Aging. <i>International Psychogeriatrics</i> , 2011 , 23, 450-8	3-4	12
79	An MRI brain atrophy and lesion index to assess the progression of structural changes in Alzheimer's disease, mild cognitive impairment, and normal aging: a follow-up study. <i>Journal of Alzheimer's Disease</i> , 2011 , 26 Suppl 3, 359-67	4-3	24
78	International development of the Unidimensional Fatigue Impact Scale (U-FIS). <i>Value in Health</i> , 2010 , 13, 463-8	3-3	14
77	International development of the patient-reported outcome indices for multiple sclerosis (PRIMUS). <i>Value in Health</i> , 2010 , 13, 946-51	3-3	25
76	A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients. <i>Quality of Life Research</i> , 2010 , 19, 1349-58	3-7	21
75	Butyrylcholinesterase activity in multiple sclerosis neuropathology. <i>Chemico-Biological Interactions</i> , 2010 , 187, 425-31	5	33
74	Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1478-86		53
73	The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1228-38	5	38

72	Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1286-94	5	26
71	Social anxiety in a multiple sclerosis clinic population. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 393-8	5	35
70	Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. <i>Value in Health</i> , 2009 , 12, 657-65	3.3	38
69	Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. <i>Cmaj</i> , 2008 , 179, 787-93	3.5	56
68	Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. <i>Cmaj</i> , 2008 , 179, 1019-26	3.5	104
67	Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 577-94	5	31
66	Comparison of cognitive functions between people with silent and wild-type butyrylcholinesterase. <i>Journal of Neural Transmission</i> , 2007 , 114, 939-45	4.3	18
65	How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?. <i>Neurology</i> , 2007 , 69, 1498-507	6.5	62
64	Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status. <i>Neuroepidemiology</i> , 2007 , 29, 201-7	5.4	13
63	Preclinical vascular cognitive impairment and Alzheimer disease: neuropsychological test performance 5 years before diagnosis. <i>Stroke</i> , 2007 , 38, 1148-53	6.7	35
62	Ethical considerations for the conduct of antidementia trials in Canada. <i>Canadian Journal of Neurological Sciences</i> , 2007 , 34 Suppl 1, S32-6	1	2
61	Disclosure of the diagnosis of dementia. <i>Alzheimeris and Dementia</i> , 2007 , 3, 404-10	1.2	33
60	Neuropsychological testing and assessment for dementia. <i>Alzheimeris and Dementia</i> , 2007 , 3, 299-317	1.2	84
59	Ethical considerations for decision making for treatment and research participation. <i>Alzheimeris and Dementia</i> , 2007 , 3, 411-7	1.2	16
58	Progressive anomia without semantic or phonological impairment. <i>Cortex</i> , 2007 , 43, 558-64	3.8	6
57	Verbal repetition in patients with Alzheimer's disease who receive donepezil. <i>International Journal of Geriatric Psychiatry</i> , 2006 , 21, 426-31	3.9	20
56	Neuropsychological detection of cognitive impairment: inter-rater agreement and factors affecting clinical decision-making. <i>Journal of the International Neuropsychological Society</i> , 2006 , 12, 72-9	3.1	8
55	Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006 , 33, 1553-8	4.1	97

54	Outcomes of incident mild cognitive impairment in relation to case definition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005 , 76, 1175-7	5.5	37
53	Disconnection of language and memory in semantic dementia: a comparative and theoretical analysis. <i>Current Alzheimer Research</i> , 2005 , 2, 435-48	3	
52	APOE genotype, vascular risk factors, memory test performance and the five-year risk of vascular cognitive impairment or Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005 , 20, 292-7	2.6	13
51	A comparison of health utility measures for the evaluation of multiple sclerosis treatments. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005 , 76, 58-63	5.5	146
50	Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 1459-6	4.1	66
49	Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. <i>Neurology</i> , 2003 , 61, 1179-84	6.5	213
48	Five-year outcomes for dementia defined solely by neuropsychological test performance. <i>Neuroepidemiology</i> , 2003 , 22, 172-8	5.4	25
47	Five-year follow-up of cognitive impairment with no dementia. <i>Archives of Neurology</i> , 2003 , 60, 577-82		171
46	Short term predictors of unemployment in multiple sclerosis patients. <i>Canadian Journal of Neurological Sciences</i> , 2003 , 30, 137-42	1	78
45	APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003 , 15, 1-5	2.6	10
44	Construction and validation of a fatigue impact scale for daily administration (D-FIS). <i>Quality of Life Research</i> , 2002 , 11, 263-72	3.7	95
43	Minimal neuropsychological assessment of MS patients: a consensus approach. <i>Clinical Neuropsychologist</i> , 2002 , 16, 381-97	4.4	459
42	Patterns and health effects of caring for people with dementia: the impact of changing cognitive and residential status. <i>Gerontologist, The</i> , 2002 , 42, 643-52	5	33
41	The effect of the living situation on the severity of dementia at diagnosis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002 , 13, 40-5	2.6	26
40	Neuropsychological predictors of incident dementia in patients with vascular cognitive impairment, without dementia. <i>Stroke</i> , 2002 , 33, 1999-2002	6.7	116
39	Societal costs of vascular cognitive impairment in older adults. <i>Stroke</i> , 2002 , 33, 1605-9	6.7	79
38	Orienting attention in aging and Parkinson's disease: distinguishing modes of control. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2002 , 24, 951-67	2.1	32
37	Improved detection of differential information-processing speed deficits between two disease-course types of multiple sclerosis.. <i>Neuropsychology</i> , 2001 , 15, 617-625	3.8	33

36	Disability and frailty among elderly Canadians: a comparison of six surveys. <i>International Psychogeriatrics</i> , 2001 , 13 Supp 1, 159-67	3.4	25
35	Limitations of the Paced Auditory Serial Addition Test as a measure of working memory in patients with multiple sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2001 , 7, 363-72	3.1	89
34	Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. <i>International Journal of Technology Assessment in Health Care</i> , 2000 , 16, 751-67	1.8	20
33	Prevalence of cognitive impairment and dementia as defined by neuropsychological test performance. <i>Neuroepidemiology</i> , 2000 , 19, 121-9	5.4	12
32	Apperceptive agnosia and face recognition. <i>Neurocase</i> , 2000 , 6, 403-414	0.8	18
31	Information processing efficiency in patients with multiple sclerosis. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2000 , 22, 686-701	2.1	127
30	Test-Retest Reliability of the Assessment of Motor and Process Skills in Elderly Adults. <i>Occupation Participation and Health</i> , 1999 , 19, 203-215		16
29	The risk of dementia and death after delirium. <i>Age and Ageing</i> , 1999 , 28, 551-6	3	291
28	The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. <i>Arthritis and Rheumatism</i> , 1999 , 42, 599-608		1533
27	A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1999 , 42, 728-34		190
26	Assessing the ADL functioning of persons with Alzheimer's disease: comparison of family informants ratings and performance-based assessment findings. <i>International Psychogeriatrics</i> , 1999 , 11, 399-409	3.4	33
25	Hospital-based psychiatric service utilization and morbidity in multiple sclerosis. <i>Canadian Journal of Neurological Sciences</i> , 1998 , 25, 230-5	1	33
24	Ethical guidelines of the Alzheimer Society of Canada. <i>Canadian Journal of Neurological Sciences</i> , 1998 , 25, 242-8	1	18
23	Measuring functional competence in older persons with Alzheimer's disease. <i>International Psychogeriatrics</i> , 1997 , 9, 25-38	3.4	40
22	Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1542-3		84
21	Psychosocial and neurological predictors of mental health in multiple sclerosis patients. <i>Journal of Clinical Epidemiology</i> , 1996 , 49, 467-72	5.7	26
20	Drug therapy in multiple sclerosis: a study of Nova Scotia senior citizens. <i>Clinical Therapeutics</i> , 1996 , 18, 303-18; discussion 302	3.5	10
19	Conceptual reasoning as a mediator of verbal recall in patients with multiple sclerosis. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1996 , 18, 211-9	2.1	9

18	Reply from the author.: <i>Canadian Journal of Neurological Sciences</i> , 1995 , 22, 75-75	1	
17	Cognitive screening in a population-based sample of community-living elderly: Effects of age and education on the construct of cognitive status. <i>International Journal of Geriatric Psychiatry</i> , 1995 , 10, 687-694	3.9	7
16	Functional competence of community-dwelling persons with multiple sclerosis using the assessment of motor and process skills. <i>Archives of Physical Medicine and Rehabilitation</i> , 1994 , 75, 843-51	2.8	66
15	Screening for cognitive impairment in the elderly: Impact of physical function measures added to cognitive screening instruments. <i>Aging, Neuropsychology, and Cognition</i> , 1994 , 1, 261-270	2.1	2
14	Brain reactive autoantibodies and cognitive impairment in systemic lupus erythematosus. <i>Lupus</i> , 1994 , 3, 193-9	2.6	17
13	Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. <i>Pain</i> , 1994 , 58, 89-98	1.6	160
12	Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. <i>Clinical Infectious Diseases</i> , 1994 , 18 Suppl 1, S79-83	11.6	945
11	The Impact of Fatigue on Patients with Multiple Sclerosis. <i>Canadian Journal of Neurological Sciences</i> , 1994 , 21, 9-14	1	714
10	A Case Control Study of the Risks for Institutionalization of Elderly People in Nova Scotia*. <i>Canadian Journal on Aging</i> , 1994 , 13, 104-117	1.6	16
9	Gravitoinertial force level influences arm movement control. <i>Journal of Neurophysiology</i> , 1993 , 69, 504-11	1.2	83
8	Tonic vibration reflexes and background force level. <i>Acta Astronautica</i> , 1992 , 26, 133-6	2.9	12
7	The Halifax Mental Status Scale: Development of a new test of mental status for use with elderly clients.. <i>Psychological Assessment</i> , 1991 , 3, 162-167	5.3	1
6	Contribution of perceptual and lexical-semantic errors to the naming impairments in Alzheimer's disease. <i>Perceptual and Motor Skills</i> , 1991 , 73, 175-83	2.2	11
5	The effects of instructions to subjects on the programming of visually directed reaching movements. <i>Journal of Motor Behavior</i> , 1989 , 21, 5-19	1.4	33
4	Orienting to Targets by Looking and Pointing: Parallels and Interactions in Ocular and Manual Performance. <i>Quarterly Journal of Experimental Psychology Section A: Human Experimental Psychology</i> , 1985 , 37, 315-338		34
3	The organization of eye and limb movements during unrestricted reaching to targets in contralateral and ipsilateral visual space. <i>Experimental Brain Research</i> , 1985 , 60, 159-78	2.3	242
2	Eye movements of human albinos. <i>Optometry and Vision Science</i> , 1984 , 61, 377-85	2.1	21
1	Contribution of Perceptual and Lexical-Semantic Errors to the Naming Impairments in Alzheimer's Disease		6

